Related Experiment Video
Updated: Jun 29, 2026
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
Published on: June 7, 2020
Surgical management of metastatic sarcoma to the brain
Benjamin D Fox1, Akash Patel, Dima Suki
1Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Houston, Texas, USA.
Object:
Metastatic sarcoma to the brain is rare and represents a therapeutic challenge due to its relative resistance to radio- and chemotherapy. Resection has traditionally been the mainstay of treatment. The authors reviewed a series of patients with metastatic sarcoma to the brain treated surgically to determine outcomes and identify predictors of survival in these patients.
Methods:
A retrospective review of prospectively collected data was undertaken on patients undergoing surgery between 1993 and 2005 for metastatic sarcoma to the brain at The University of Texas, M.D. Anderson Cancer Center.
Results:
During the study period, 62 patients underwent 84 operations for metastatic sarcoma to the brain. The median postoperative overall and progression-free survival rates were 7.5 and 4.7 months, respectively. Fifty-nine (95%) of 62 patients had a gross-total resection. The 30-day mortality rate was 4.2%. The Karnofsky Performance Scale scores at discharge from the hospital and 3 months postoperatively were the same or improved in 50 (85%) of 59 and 26 (51%) of 51, respectively. Overall postcraniotomy survival was 62% at 6 months, 39% at 1 year, 21% at 2 years, and 8% at 5 years. In multivariate and univariate analysis, control of systemic disease, and sarcomas originating from bone, cartilage, or soft tissue were predictors of survival. Patients with control of systemic disease had survival advantage when compared with those who did not. In patients with alveolar soft-part sarcoma, there was a significantly increased survival advantage compared with all other histological subgroups.
Conclusions:
The authors' results suggest that in selected patients, resection of metastatic sarcoma to the brain is associated with a relatively low risk of operative death and results in improvement in neurological function. Patients with systemic control of their primary disease and certain histological subtypes (specifically alveolar soft-part sarcoma) have improved overall and progression-free survival.
Insights
Surgical resection of brain metastases from sarcoma offers improved survival, especially when systemic disease is controlled. Alveolar soft-part sarcoma patients showed significantly better outcomes after brain surgery.
Area of Science:
- Neurosurgery
- Oncology
- Pathology
Background:
- Metastatic sarcoma to the brain is rare and challenging to treat.
- Brain metastases are often resistant to conventional therapies like radiation and chemotherapy.
- Surgical resection is a primary treatment modality for these lesions.
Purpose of the Study:
- To evaluate outcomes of surgical treatment for brain metastases from sarcoma.
- To identify predictors of survival in patients undergoing resection.
Main Methods:
- Retrospective review of prospectively collected data.
- Analysis of patients who underwent surgery for brain metastases between 1993 and 2005.
- Inclusion of 62 patients undergoing 84 operations.
Main Results:
- Median overall survival was 7.5 months; progression-free survival was 4.7 months.
- Gross-total resection achieved in 95% of patients with a 4.2% 30-day mortality.
- Predictors of survival included systemic disease control and specific histological subtypes like alveolar soft-part sarcoma.
Conclusions:
- Resection of brain metastases from sarcoma is associated with low operative risk and improved neurological function in selected patients.
- Systemic disease control and specific histological subtypes, particularly alveolar soft-part sarcoma, are linked to better survival.
- Surgical intervention can be a valuable part of the multidisciplinary approach for managing brain metastases from sarcoma.
